These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31462766)

  • 21. Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder.
    Chin Fatt CR; Cooper CM; Jha MK; Minhajuddin A; Rush AJ; Trombello JM; Fava M; McInnis M; Weissman M; Trivedi MH
    J Affect Disord; 2021 Mar; 282():602-610. PubMed ID: 33445082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the glucocorticoid receptor BclI polymorphism on reward expectancy and prediction error related ventral striatal reactivity in depressed and healthy individuals.
    Ham BJ; Greenberg T; Chase HW; Phillips ML
    J Psychopharmacol; 2016 Jan; 30(1):48-55. PubMed ID: 26349556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients.
    Trombello JM; Killian MO; Grannemann BD; Rush AJ; Mayes TL; Parsey RV; McInnis M; Jha MK; Ali A; McGrath PJ; Adams P; Oquendo MA; Weissman MM; Carmody TJ; Trivedi MH
    J Psychopharmacol; 2019 Feb; 33(2):185-193. PubMed ID: 30652941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reward Behavior Disengagement, a Neuroeconomic Model-Based Objective Measure of Reward Pathology in Depression: Findings from the EMBARC Trial.
    Giles MA; Cooper CM; Jha MK; Chin Fatt CR; Pizzagalli DA; Mayes TL; Webb CA; Greer TL; Etkin A; Trombello JM; Chase HW; Phillips ML; McInnis MG; Carmody T; Adams P; Parsey RV; McGrath PJ; Weissman M; Kurian BT; Fava M; Trivedi MH
    Behav Sci (Basel); 2023 Jul; 13(8):. PubMed ID: 37622759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study.
    Jha MK; Minhajuddin A; Chin Fatt C; Trivedi MH
    J Affect Disord; 2020 Oct; 275():44-47. PubMed ID: 32658822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder.
    Tan A; Costi S; Morris LS; Van Dam NT; Kautz M; Whitton AE; Friedman AK; Collins KA; Ahle G; Chadha N; Do B; Pizzagalli DA; Iosifescu DV; Nestler EJ; Han MH; Murrough JW
    Mol Psychiatry; 2020 Jun; 25(6):1323-1333. PubMed ID: 30385872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial.
    Barber JP; Barrett MS; Gallop R; Rynn MA; Rickels K
    J Clin Psychiatry; 2012 Jan; 73(1):66-73. PubMed ID: 22152401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Neural and Emotional Impacts of Reward Prediction Errors With Major Depression.
    Rutledge RB; Moutoussis M; Smittenaar P; Zeidman P; Taylor T; Hrynkiewicz L; Lam J; Skandali N; Siegel JZ; Ousdal OT; Prabhu G; Dayan P; Fonagy P; Dolan RJ
    JAMA Psychiatry; 2017 Aug; 74(8):790-797. PubMed ID: 28678984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Liu Y; Admon R; Mellem MS; Belleau EL; Kaiser RH; Clegg R; Beltzer M; Goer F; Vitaliano G; Ahammad P; Pizzagalli DA
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2020 Feb; 5(2):163-172. PubMed ID: 31784354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial.
    Cooper CM; Chin Fatt CR; Jha M; Fonzo GA; Grannemann BD; Carmody T; Ali A; Aslan S; Almeida JRC; Deckersbach T; Fava M; Kurian BT; McGrath PJ; McInnis M; Parsey RV; Weissman M; Phillips ML; Lu H; Etkin A; Trivedi MH
    EClinicalMedicine; 2019 Apr; 10():32-41. PubMed ID: 31193824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
    Grieve SM; Korgaonkar MS; Gordon E; Williams LM; Rush AJ
    J Clin Psychiatry; 2016 Apr; 77(4):e436-43. PubMed ID: 27137427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of EEG in depression after antidepressant treatment with sertraline? A preliminary report.
    van der Vinne N; Vollebregt MA; Boutros NN; Fallahpour K; van Putten MJAM; Arns M
    J Affect Disord; 2019 Dec; 259():67-72. PubMed ID: 31437703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neural mechanisms of reinforcement learning in unmedicated patients with major depressive disorder.
    Rothkirch M; Tonn J; Köhler S; Sterzer P
    Brain; 2017 Apr; 140(4):1147-1157. PubMed ID: 28334960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exercise and pharmacotherapy in the treatment of major depressive disorder.
    Blumenthal JA; Babyak MA; Doraiswamy PM; Watkins L; Hoffman BM; Barbour KA; Herman S; Craighead WE; Brosse AL; Waugh R; Hinderliter A; Sherwood A
    Psychosom Med; 2007; 69(7):587-96. PubMed ID: 17846259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.
    Ang YS; Kaiser R; Deckersbach T; Almeida J; Phillips ML; Chase HW; Webb CA; Parsey R; Fava M; McGrath P; Weissman M; Adams P; Deldin P; Oquendo MA; McInnis MG; Carmody T; Bruder G; Cooper CM; Chin Fatt CR; Trivedi MH; Pizzagalli DA
    Biol Psychiatry; 2020 Oct; 88(8):657-667. PubMed ID: 32507389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
    Mischoulon D; Hylek L; Yeung AS; Clain AJ; Baer L; Cusin C; Ionescu DF; Alpert JE; Soskin DP; Fava M
    J Affect Disord; 2017 Jan; 208():6-14. PubMed ID: 27736689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.